Telomir Pharmaceuticals, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.9352 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 68.85M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson’s disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer’s disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Details
| Name | Telomir Pharmaceuticals, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Founded | 2021 |
| Ipo Date | 2024-02-09 |
| Ceo | Erez Aminov |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 7.00 |
| Isin | US87975F1049 |
| Cusip | 87975F104 |
| Cik | 1971532 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Erez Aminov | Chairman of the Board and Chief Executive Officer |
| Andriy Mushak CPA | Chief Financial Officer |
| Dr. Itzchak Angel Ph.D. | Chief Scientific Advisor |
Contact
| Address | 100 SE 2nd Street, Suite 2000 #1009, Miami, Florida 33131, United States |
| Phone | 786 396 6723 |
| Website | https://telomirpharma.com |